DAX-0,41 % EUR/USD-0,05 % Gold+0,41 % Öl (Brent)+0,24 %

ChromaDex (smallcap) - A Philipp Frost (Billionair) Investment (Seite 11)



Beitrag schreiben

Begriffe und/oder Benutzer

 

http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://www.en.auh.dk/
http://www.ku.dk/english/

https://academic.oup.com/ajcn/advance-article/doi/10.1093/aj…
"Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and Shows Potential for Improvement in Liver Health; Findings from Aarhus University Hospital and the University of Copenhagen Suggest Further Studies on NIAGEN® Should Focus on Therapeutic Potential for Liver Health

IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen and Aarhus University Hospital, were published yesterday in The American Journal of Clinical Nutrition. The study was led by Jonas T. Treebak, MS, PhD and Niels Jessen, MD, PhD.

The authors conducted a 12-week, randomized, double-blinded, placebo-controlled, parallel-group clinical trial in 40 middle-aged obese men taking a 2 gram dose (1 gram twice daily) of NIAGEN nicotinamide riboside chloride (NR). This is the fourth published clinical study of NR, and the results of this study corroborate previous findings that NR effectively raises levels of nicotinamide adenine dinucleotide (NAD) in humans without adverse effects. This study represents the highest dose, longest-term clinical investigation of NR supplementation to date.

Dr. Charles Brenner, discoverer of NR as a form of vitamin, Chief Scientific Advisor of ChromaDex and co-author of the study commented, “Though previous work established safety of NR in older adults, we needed to look at safety of NR in other populations. In this study, we clearly showed that 2 grams per day of NR is safe in obese men and we were able to assess which metabolic parameters are most sensitive to NR supplementation.” Dr. Brenner serves as the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa.

In addition to confirming the ability of high dose NIAGEN to effectively and tolerably raise NAD levels in obese men, the study assessed a broad range of metabolic factors related to metabolic syndrome and obesity. The authors observed that men taking NR had an average 2% absolute reduction in liver fat content compared to a 0.2% absolute reduction in the placebo group (P=0.13). The authors also looked at the subset of men who started the trial with greater than 5% liver fat. They found a trend that 69% of these men experienced a reduction in liver fat after 12 weeks of NIAGEN compared to only 39% of the men taking the placebo.

The results of this study provide important clues for the role of NIAGEN in supporting liver health and support the need for future clinical studies to determine the effects of NR on liver health in both longer trials and in more diverse populations. “This study supports the safety of high dose NR in obese men and, with further testing, may demonstrate that it provides a beneficial nutritional intervention to reduce liver fat,” said Dr. Brenner.

To date, ChromaDex has invested millions in safety, toxicology and human clinical trials on NIAGEN, the only form of NR with New Dietary Ingredient and Generally Regarded as Safe designations notified to the US Food and Drug Administration. ChromaDex has supplied NIAGEN at no cost to over 140 leading institutions for research including Dartmouth, the National Institutes of Health, University of Iowa, and the Scripps Research Institute.

To learn more about ChromaDex, please visit www.ChromaDex.com.

About NIAGEN®:
NIAGEN®, also known as nicotinamide riboside (NR), is a very unique member of the vitamin B3 family. The body converts NR into Nicotinamide Adenine Dinucleotide (NAD) which is an essential molecule found in every living cell.

About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER®. To learn more about ChromaDex, please visit www.ChromaDex.com."
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://english.jiangxi.gov.cn/
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
"ChromaDex Announces Strategic Partnership for Aging Research with Jiangxi Government in China; New partnership between ChromaDex and First Affiliated Hospital of Nanchang University addresses China’s rapidly aging population

IRVINE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced a strategic partnership for healthy aging research with the Jiangxi Provincial Government, People’s Republic of China.

Wu Zhongqiong, Vice Governor of the People’s Government of Jiangxi Province, commenced the ceremony at the Jiangxi Qianhu State Guesthouse on Thurs., Sept. 13. Additional presentations followed from Madame Wang of Qifeng Food Technology, Dr. Katherine Lo of the Li Ka Shing Foundation, Robert Fried of ChromaDex, and Drs. Charles Brenner and Roger Kornberg of the ChromaDex Scientific Advisory Board.

“We are grateful to have met with the leaders of the great province of Jiangxi and look forward to furthering this relationship,” says ChromaDex CEO Rob Fried. “This is an important first step in our long-term commitment to China.”

“This is a momentous occasion here in Jiangxi,” says Kornberg, who won the Nobel Prize in Chemistry in 2006. “I look forward to the research and progress in the study of aging that will come from this new initiative.”

"I’m thrilled to present the foundational science of nicotinamide riboside (NR) and the safe, evidence-based commercialization of our ingredient to Nanchang and Jiangxi Province,” says Brenner. “The global interest in our technology is exciting, and I look forward to advancing our research and development even further." Brenner discovered NR and is the Chief Scientific Advisor at ChromaDex.

The initiative will allow Jiangxi to become a foothold for advanced scientific research and business development to solve the problem of aging. The parties continue to discuss the details of the relationship, including their respective contributions to the venture, with the anticipation of finalizing definitive agreements later this year.

In addition to the anti-aging initiative, the ceremony also celebrated the launch of the Food Technology Science Park, in collaboration with Qifeng Food Technology Co. of Beijing, to build a world-class, tech-centric science research complex in Jiangxi.

For additional information on the science supporting TRU NIAGEN visit www.truniagen.com.

About TRU NIAGEN®:
TRU NIAGEN® is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN® nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN® has twice been successfully reviewed under FDA's new dietary ingredient (“NDI”) notification program, and has also been successfully notified to the FDA as generally recognized as safe (“GRAS”).

About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company."
 Durchsuchen


Beitrag zu dieser Diskussion schreiben